Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-145 in advanced malignancies
NCT03922204Phase 1Completed
- Sponsor
- Merus
- Start
- May 2019
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of MCLA-145 in solid tumor (advanced stage) and B cell lymphoma (2 arms), sponsored by Merus. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events at 90 days. Started May 2019; status: completed.
02
Drugs
MCLA-145
03
Conditions
solid tumor (advanced stage)B cell lymphoma
Beyond the preview
Go deeper on NCT03922204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922204.